[Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder]
Maki Numajiri1, Jun Aoki, Kazuhiko Iwahashi
1Neurophysiology, Graduate School of Environmental Health Sciences, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara 252-5201, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
|July 28, 2012
Summary
Glycogen synthase kinase 3 beta (GSK-3beta) gene variations may predict lithium treatment response in bipolar disorder patients. A specific GSK-3beta-50T/C polymorphism showed a higher T-allele frequency in lithium responders.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Glycogen synthase kinase 3 beta (GSK-3beta) is an enzyme targeted by mood stabilizers like lithium.
- Genetic variations (polymorphisms) in GSK-3beta may influence treatment efficacy.
Purpose of the Study:
- To investigate the association between GSK-3beta gene polymorphisms (-50T/C and -1727A/T) and lithium treatment response in Japanese bipolar disorder patients.
Main Methods:
- Genotyping of GSK-3beta-50T/C and -1727A/T single nucleotide polymorphisms (SNPs).
- Analysis of allele frequencies in lithium responders versus non-responders among 29 bipolar patients.
Main Results:
- A significant association was found between the GSK-3beta-50T/C polymorphism and lithium response.
- The T-allele of GSK-3beta-50T/C was significantly more frequent in lithium responders (P < 0.01).
- No significant association was observed for the GSK-3beta-1727A/T polymorphism.
Conclusions:
- The GSK-3beta-50T/C polymorphism may serve as a genetic marker for predicting lithium treatment response in bipolar disorder.
- Further research is warranted to validate these findings in larger cohorts.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:30Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...